171 related articles for article (PubMed ID: 1682037)
1. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
van der Zee AG; Hollema H; de Jong S; Boonstra H; Gouw A; Willemse PH; Zijlstra JG; de Vries EG
Cancer Res; 1991 Nov; 51(21):5915-20. PubMed ID: 1682037
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
3. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
5. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
[TBL] [Abstract][Full Text] [Related]
6. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
7. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
11. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
12. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
[TBL] [Abstract][Full Text] [Related]
13. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
14. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
17. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
18. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
[TBL] [Abstract][Full Text] [Related]
20. Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells.
Sharma R; Arnold L; Gulliya KS
Anticancer Res; 1995; 15(2):295-304. PubMed ID: 7762997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]